Aurinia PharmaceuticalsAUPH +1.07%82 Days Payable is 41.90 as of Mar. 2026, which is 74% below its 10-year median of 160.05. GuruFocus rates AUPH with a GF Score™ of 82/100 and a GF Value™ of $13.99 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 704 Biotechnology companies, Aurinia Pharmaceuticals ranks worse than 75.71% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Aurinia Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aurinia Pharmaceuticals Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aurinia Pharmaceuticals's Days Payable distribution charts can be found below:
* The bar in red indicates where Aurinia Pharmaceuticals's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Aurinia Pharmaceuticals's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aurinia Pharmaceuticals (AUPH) has a Days Payable of 41.90 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Aurinia Pharmaceuticals and its competitors. This is 74% below median its historical median of 160.05. Over the past decade, Aurinia Pharmaceuticals' Days Payable has ranged from 37.51 to 225,478.75. According to the industry distribution chart, Aurinia Pharmaceuticals ranks #533 out of 704 companies in the Biotechnology industry, placing it in the top 75.7%.
Is Aurinia Pharmaceuticals' Days Payable too high?
Aurinia Pharmaceuticals' current Days Payable of 41.90 is 74% below median its 10-year median of 160.05. Over the past 10 years, this metric has ranged from a low of 37.51 to a high of 225,478.75. The Biotechnology industry median Days Payable is 113.56. Aurinia Pharmaceuticals' value of 41.90 is 63.1% below this industry median. Based on the distribution chart, Aurinia Pharmaceuticals ranks #533 out of 704 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Aurinia Pharmaceuticals has a GF Score™ of 82/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aurinia Pharmaceuticals' Days Payable compare to KOD and ABCL?
According to the Biotechnology industry distribution chart, Aurinia Pharmaceuticals ranks #533 out of 704 companies for Days Payable. This places Aurinia Pharmaceuticals in the lower half of its industry. The industry median Days Payable is 113.56. Aurinia Pharmaceuticals' value of 41.90 is 63.1% below this benchmark. Historically, Aurinia Pharmaceuticals' own Days Payable has ranged from 37.51 to 225,478.75 over the past decade. While the company's 10-year median is 160.05 vs. the industry median of 113.56, Aurinia Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aurinia Pharmaceuticals's current Days Payable of 41.90 is 63.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Aurinia Pharmaceuticals and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aurinia Pharmaceuticals's current Days Payable is 41.90, which is 74% below median its own 10-year median of 160.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aurinia Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Aurinia Pharmaceuticals (AUPH) is currently considered Modestly Overvalued. The stock's GF Value™ is $13.99, compared to a current price of $16.97 — trading 21.3% above its estimated fair value. The current Days Payable is 41.90, which is 74% below median its 10-year median of 160.05 and 63.1% below the Biotechnology industry median of 113.56. Aurinia Pharmaceuticals' overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Aurinia Pharmaceuticals (AUPH), the current Days Payable is 41.90 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aurinia Pharmaceuticals (AUPH) Overvalued in 2026?
Based on GuruFocus' analysis, Aurinia Pharmaceuticals stock appears to be overvalued.
The current stock price of $16.97 is trading 21.3% above its estimated GF Value™ of $13.99.
GuruFocus considers Aurinia Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for AUPH:
Days Payable: 41.90 (74% below median its 10-year median of 160.05)
GF Value™: $13.99 vs. price of $16.97 (21.3% above fair value)
Industry Position: 63.1% below the Biotechnology median (#533 of 704)
No single metric tells the full story. See the AUPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
82GF Score
Get the complete analysis for AUPH
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AUPH has been successfully added to your 
